High-Precision Post-Transcriptional Gene Silencing for Research and Therapeutics. RNA Interference (RNAi) is a natural biological process in which RNA molecules inhibit gene expression or translation by neutralizing targeted mRNA molecules. CD Biosynsis provides professional RNA Interference (RNAi) Services, offering a comprehensive suite of tools including siRNA, shRNA, and dsRNA to achieve robust and specific gene knockdown. By leveraging the endogenous RISC pathway, our platform enables researchers to perform loss-of-function studies, validate drug targets, and develop sustainable biological solutions across human health, agriculture, and industrial biotechnology.
Get a Technical QuoteOur RNAi platform is designed for versatility, supporting projects ranging from transient cellular knockdown to large-scale biological pesticide manufacturing. We focus on achieving maximum silencing potency with minimal off-target effects.
| Service Tier | Technical Focus | Primary Application | Strategic Value |
|---|---|---|---|
| Custom siRNA Synthesis | Chemically modified transient silencing | In vitro target validation & Screening | Rapid, high-potency gene suppression |
| shRNA Lentiviral Services | Vector-based permanent knockdown | Stable cell line generation | Long-term gene silencing and selection |
| Industrial dsRNA Production | Microbial fermentation scaling | Agricultural biopesticides | Low-cost, high-volume RNA manufacturing |
| RNAi Drug Delivery Design | LNP & Conjugate-mediated delivery | Pre-clinical therapeutic development | Optimizes stability and tissue targeting |
| Genome-wide RNAi Screening | Pooled or arrayed library screens | Novel disease pathway discovery | Identifies essential genes and lethal targets |
1. Sequence Design
2. Synthesis & Modification
3. Delivery Optimization
4. Phenotypic Validation
Selection of optimal target sites and bioinformatic screening against the transcriptome to ensure high specificity and potency.
Project feasibility assessment and Mutual NDA signing.
Precision synthesis of siRNA/dsRNA or construction of shRNA expression vectors with customized chemical modifications.
Tailoring RNA architecture for enhanced stability in various biological environments.
Optimization of delivery methods such as LNPs, viral vectors, or topical application tailored to the target cell or organism.
In vitro or in vivo pilot testing to determine optimal dosage and delivery efficiency.
Rigorous assessment of mRNA depletion via RT-qPCR and protein reduction via Western Blot, followed by phenotypic analysis.
Final delivery of validated RNAi tools and comprehensive characterization dossiers.
To deliver superior gene silencing results, we benchmark our protocols against landmark RNAi research.
RNAi is foundational for deconstructing oncogenic drivers. Benchmarks have successfully utilized siRNA to silence the FLT3 gene in leukemia cell lines. By targeting FLT3 mRNA for degradation via the RISC complex, researchers inhibited protein synthesis and membrane expression, providing a powerful methodology for cancer driver studies.
(Reference: RNA interference protocol for leukemia, 2022)
The clinical translation of RNAi has led to significant breakthroughs, such as the drug Inclisiran. Designed to specifically inhibit the PCSK9 gene, this RNAi therapeutic significantly lowers cholesterol levels. This highlights the potential of RNAi for long-term clinical management of cardiovascular health.
(Reference: RNA interference in Cardiovascular Innovation, 2024)
RNAi reached a milestone with the commercialization of sprayable RNA biopesticides. In 2023, the first RNAi-based biopesticide was approved for Colorado Potato Beetle control. By delivering specific dsRNA that interferes with essential genes, this technology offers a species-specific and environmentally friendly alternative to chemical pesticides.
(Reference: RNAi technology in potato pest control, 2024)
To support commercialization, cost-effective manufacturing is essential. Advanced platforms utilize engineered microbial fermentation systems to achieve high-yield overproduction of dsRNA. This solves traditional cost barriers and facilitates the large-scale application of RNAi biopesticides and antiviral agents.
(Reference: Microbial Overproduction Systems for dsRNA, 2022)
1. How long does the silencing effect typically last?
Standard siRNA transfection typically results in knockdown for 3–7 days. For stable, long-term silencing (weeks or months), we recommend our shRNA lentiviral integration services.
2. Can you design RNAi for non-model organisms or pests?
Yes. Our bioinformatic platform can design specific RNAi sequences for any organism with a sequenced transcriptome, including specialized agricultural pests and aquatic species.
3. What is the advantage of dsRNA over traditional chemical pesticides?
dsRNA is highly species-specific, meaning it only affects the target pest and does not harm beneficial insects like bees. It also degrades naturally in the environment.
4. How do you prevent siRNA from triggering an immune response?
We use specialized chemical modifications and selection algorithms to avoid motifs known to trigger TLR7/8 or interferon pathways, ensuring clean data and high cell viability.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.